FeesSafety
Pluang+

Altisource's Q3 2026 service revenue rises 26%, with improved adjusted EBITDA and strategic growth plans.

Company Fundamentals
29 Oct 2026, 14:22 WIB
GlobeNewsWire
View Source
Bullish
Altisource's Q3 2026 service revenue rises 26%, with improved adjusted EBITDA and strategic growth plans.

Altisource Portfolio Solutions reported a 26% increase in service revenue to $49.8 million for Q3 2026 compared to the same period last year, driven by new customer wins and growth outside key clients. Adjusted EBITDA rose 17% to $4.3 million, reflecting operational improvements despite a slight margin decline due to investments. The company aims to reach $45 million run-rate Adjusted EBITDA by Q4 2028 through Project 45, focusing on scalability and efficiency with AI initiatives. Despite a net loss of $1.4 million, Altisource improved its financial position with increased cash flow and reduced losses year-over-year.

Altisource Portfolio Solutions announced a 26% rise in service revenue to $49.8 million for Q3 2026. For readers following the Real Estate sector, here is Pluang's market snapshot as of Oct 29, 2026 17:51 WIB: out of 47 priced US Real Estate stocks, 39 rose and 7 fell. Notable movers include CTRE at USD 35.93 (+1.35%), AMH at USD 31.59 (+1.25%), and O at USD 56.92 (+1.23%) with a typical hold time of 129 days and Pluang order activity of 52% Sell / 48% Buy.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App